China Resources Pharmaceutical Group Limited
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese… Read more
China Resources Pharmaceutical Group Limited (640) - Net Assets
Latest net assets as of June 2025: €112.03 Billion EUR
Based on the latest financial reports, China Resources Pharmaceutical Group Limited (640) has net assets worth €112.03 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€286.85 Billion) and total liabilities (€174.81 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €112.03 Billion |
| % of Total Assets | 39.06% |
| Annual Growth Rate | 7.67% |
| 5-Year Change | 22.56% |
| 10-Year Change | N/A |
| Growth Volatility | 8.86 |
China Resources Pharmaceutical Group Limited - Net Assets Trend (2016–2024)
This chart illustrates how China Resources Pharmaceutical Group Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for China Resources Pharmaceutical Group Limited (2016–2024)
The table below shows the annual net assets of China Resources Pharmaceutical Group Limited from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €98.09 Billion | +5.50% |
| 2023-12-31 | €92.97 Billion | +3.10% |
| 2022-12-31 | €90.18 Billion | -5.06% |
| 2021-12-31 | €94.98 Billion | +18.69% |
| 2020-12-31 | €80.03 Billion | +15.01% |
| 2019-12-31 | €69.58 Billion | +14.96% |
| 2018-12-31 | €60.53 Billion | -4.13% |
| 2017-12-31 | €63.14 Billion | +16.27% |
| 2016-12-31 | €54.30 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to China Resources Pharmaceutical Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 90.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €31.44 Billion | 65.17% |
| Other Components | €16.80 Billion | 34.83% |
| Total Equity | €48.24 Billion | 100.00% |
China Resources Pharmaceutical Group Limited Competitors by Market Cap
The table below lists competitors of China Resources Pharmaceutical Group Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Granules India Limited
NSE:GRANULES
|
$940.74 Million |
|
SHANGH.DAZ.PUBL.UTIL.YC 1
F:6WL
|
$940.78 Million |
|
Retail Estates N.V.
LSE:0FSO
|
$940.86 Million |
|
Asian Star Anchor Chain Co Ltd Jiangsu
SHG:601890
|
$941.63 Million |
|
Jiangsu Baichuan HighTech New Materials Co Ltd
SHE:002455
|
$940.60 Million |
|
Luoniushan Co Ltd
SHE:000735
|
$939.65 Million |
|
Green Thumb Industries Inc
OTCQX:GTBIF
|
$939.64 Million |
|
Xinyu Iron & Steel Co Ltd
SHG:600782
|
$939.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China Resources Pharmaceutical Group Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 45,959,605,000 to 48,244,236,000, a change of 2,284,631,000 (5.0%).
- Net income of 3,350,857,000 contributed positively to equity growth.
- Dividend payments of 1,488,955,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €3.35 Billion | +6.95% |
| Dividends Paid | €1.49 Billion | -3.09% |
| Other Changes | €422.73 Million | +0.88% |
| Total Change | €- | 4.97% |
Book Value vs Market Value Analysis
This analysis compares China Resources Pharmaceutical Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €6.66 | €0.50 | x |
| 2018-12-31 | €6.27 | €0.50 | x |
| 2019-12-31 | €6.48 | €0.50 | x |
| 2020-12-31 | €7.40 | €0.50 | x |
| 2021-12-31 | €8.11 | €0.50 | x |
| 2022-12-31 | €7.89 | €0.50 | x |
| 2023-12-31 | €7.32 | €0.50 | x |
| 2024-12-31 | €7.68 | €0.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China Resources Pharmaceutical Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.95%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.30%
- • Asset Turnover: 1.00x
- • Equity Multiplier: 5.34x
- Recent ROE (6.95%) is below the historical average (8.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 7.50% | 1.80% | 1.17x | 3.56x | €-940.62 Million |
| 2017 | 8.32% | 2.02% | 1.07x | 3.84x | €-703.94 Million |
| 2018 | 10.26% | 2.13% | 1.08x | 4.48x | €100.56 Million |
| 2019 | 8.07% | 1.61% | 1.08x | 4.67x | €-784.72 Million |
| 2020 | 7.10% | 1.65% | 0.96x | 4.51x | €-1.35 Billion |
| 2021 | 7.39% | 1.59% | 0.95x | 4.88x | €-1.33 Billion |
| 2022 | 8.37% | 1.63% | 1.05x | 4.87x | €-808.53 Million |
| 2023 | 8.39% | 1.58% | 0.99x | 5.37x | €-741.71 Million |
| 2024 | 6.95% | 1.30% | 1.00x | 5.34x | €-1.47 Billion |
Industry Comparison
This section compares China Resources Pharmaceutical Group Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $251,273,030
- Average return on equity (ROE) among peers: -103.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China Resources Pharmaceutical Group Limited (640) | €112.03 Billion | 7.50% | 1.56x | $940.63 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |